Jacob Bor
Profiles

Jacob Bor, SD

Associate Professor, Global Health - Boston University School of Public Health

617-358-2176
jbor@bu.edu
Crosstown Center
View Full Profile at BUMC

Biography

Jacob Bor, ScD, is an Associate Professor in the Departments of Global Health and Epidemiology at Boston University School of Public Health. His research applies the analytical tools of economics and data science to the study of population health. Research interests include HIV treatment and prevention in southern Africa, structural causes of health disparities in the U.S, and intersections of health, politics, and development. Prior to his graduate training at Harvard School of Public Health, Dr. Bor worked with an HIV-prevention NGO in Botswana, Lesotho, and South Africa. He is a faculty affiliate of BU's Global Development Policy Center and Senior Research at the Health Economics and Epidemiology Research Office (www.heroza.org) in South Africa.

Other Positions

  • Associate Professor, Epidemiology - Boston University School of Public Health

Education

  • Harvard School of Public Health, SD Field of Study: Global Health Management
  • Harvard School of Public Health, SM/ScM Field of Study: Economics
  • Harvard College, AB Field of Study: Social Sciences

Websites

Classes Taught

  • SPHPH720

Publications

  • Published on 5/1/2026

    Bor J, Raquib RV, Himmelstein D, Woolhandler S, Stokes AC. Causes of Excess Deaths in the US Compared With Other High-Income Countries. JAMA Netw Open. 2026 May 01; 9(5):e266147. PMID: 42101842.

     Read At: PubMed
  • Published on 4/30/2026

    Zheng A, Murray EJ, Brennan AT, Greener R, Kileel EM, Bor J, Venter WDF, Pisa PT, Fox MP, Maskew M. One- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials. Open Forum Infect Dis. 2026 May; 13(5):ofag151. PMID: 42078192.

     Read At: PubMed
  • Published on 3/10/2026

    Zheng A, Fox MP, Greener R, Kileel EM, Bor J, Venter WD, Pisa PT, Murray EJ, Brennan AT, Maskew M. Initiation of dolutegravir vs efavirenz on 12- and 24-month weight, body mass index, blood pressure, and incident hypertension: A target trial emulation. Ann Epidemiol. 2026 May; 117:110074. PMID: 41819297.

     Read At: PubMed
  • Published on 3/1/2026

    Onoya D, Shumba K, Mudara C, Nattey C, Gareta D, Lauren E, Macleod W, Fox MP, Mlisana K, Bor J. Timing of ART Initiation With Treatment Policy Changes in South Africa: A Cohort Study. J Acquir Immune Defic Syndr. 2026 Mar 01; 101(3):316-324. PMID: 41252684.

     Read At: PubMed
  • Published on 2/7/2026

    Gareta D, Lauren E, Shumba K, Nattey C, Fox MP, Mlisana K, Egger M, Onoya D, Herbst K, Bor J. Linkage of HIV treatment and population-based surveillance records in rural South Africa: the AHRI Unified Data Platform (AUDP). Arch Public Health. 2026 Feb 07; 84(1). PMID: 41652614.

     Read At: PubMed
  • Published on 12/1/2025

    Calabrese SK, Bor J, Dukashe M, Kalwicz DA, Mupeli K, Onoya D, Stackpool-Moore L, Richman B. A call to action to advance global research priorities related to Undetectable = Untransmittable. J Int AIDS Soc. 2025 Dec; 28(12):e70069. PMID: 41414745.

     Read At: PubMed
  • Published on 12/1/2025

    Dzomba A, Shumba K, Nattey C, Lauren E, Brennan AT, McLoed W, Fox MP, Bor J, Onoya D. HIV Patient Treatment Adherence Trajectories in First 24 months After ART Initiation Among Adults: An Electronic Health Records Cohort From South Africa. J Acquir Immune Defic Syndr. 2025 Dec 01; 100(4):305-314. PMID: 40778758.

     Read At: PubMed
  • Published on 10/21/2025

    Brennan AT, Lauren E, Bor J, George JA, Khoza S, Mlisana K, Kileel EM, Rosen S, Raal F, Hibberd P, Fox MP, Crowther NJ. Gaps in the Type 1 Diabetes Mellitus care cascade: a national perspective using South Africa's National Health Laboratory Service (NHLS) database. medRxiv. 2025 Oct 21. PMID: 41040711.

     Read At: PubMed
  • Published on 9/22/2025

    Zheng A, Brennan AT, Greener R, Kileel EM, Bor J, Venter WDF, Murray EJ, Pisa PT, Goeieman B, Fox MP, Maskew M. Initiation of dolutegravir vs. efavirenz on 12- and 24-month retention and viral suppression: a target trial emulation. Infect Dis (Lond). 2026 Feb; 58(2):198-208. PMID: 40982349.

     Read At: PubMed
  • Published on 9/8/2025

    Lauren E, Shumba K, Fox MP, MacLeod W, Stevens W, Mlisana K, Bor J, Onoya D. Correction: The fall-And rise-In hospital-based care for people with HIV in South Africa: 2004-2017. PLOS Glob Public Health. 2025; 5(9):e0005169. PMID: 40920701.

     Read At: PubMed

View 133 more publications:View Full Profile at BUMC

News & In the Media

View all profiles